Abstract
Objective: The case aims to show anti-proteinuric effect of Chinese herbal medicines (CHM) in a patient with heavy proteinuric non-IgA mesangial proliferative glomerulonephritis (MsPGN). Subject: A 16-year-old boy was found edema in the lower limbs and a great quantity of urine protein for 4-months and diagnosed as non-IgA MsPGN via renal biopsy later, but there was no amelioration after receiving a shortdated comprehensive treatment including full amount of prednisone. Then he visited Prof. Ming Wan for traditional Chinese medicine (TCM) therapy. Interventions and outcome: This patient was treated with the integrated treatment, mainly including empirical Chinese herbal formulas (500 mL/day for 3-months), multi-glycoside of Tripterygium wilfordii Hook.f. (GTW) (90 mg/day for 3-months) and Losartan (50 mg/day for 3-months). His heavy proteinuria and clinical conditions were significantly improved after continuous treatment for 3-months and basically stable for nearly 3-years during the follow-up. Conclusions: Based on a variety of conventional drugs in clinic, the combined treatment of empirical Chinese herbal formulas and GTW was significantly effective in reducing massive proteinuria in non-IgA MsPGN patients, which is different from hormonotherapy.
Keywords: Case report, Chinese herbal medicines, multi-glycoside of Tripterygium wilfordii Hook.f. (GTW), Non-IgA mesangial proliferative glomerulonephritis, proteinuria.
Current Traditional Medicine
Title:A Case of Heavy Proteinuric Non-IgA Mesangial Proliferative Glomerulonephritis Ameliorated by Chinese Herbal Medicines
Volume: 1 Issue: 3
Author(s): Yan-ru Huang, Thomas Heaton, Yi-gang Wan, Zhi-min Mao and Jing-jing Yang
Affiliation:
Keywords: Case report, Chinese herbal medicines, multi-glycoside of Tripterygium wilfordii Hook.f. (GTW), Non-IgA mesangial proliferative glomerulonephritis, proteinuria.
Abstract: Objective: The case aims to show anti-proteinuric effect of Chinese herbal medicines (CHM) in a patient with heavy proteinuric non-IgA mesangial proliferative glomerulonephritis (MsPGN). Subject: A 16-year-old boy was found edema in the lower limbs and a great quantity of urine protein for 4-months and diagnosed as non-IgA MsPGN via renal biopsy later, but there was no amelioration after receiving a shortdated comprehensive treatment including full amount of prednisone. Then he visited Prof. Ming Wan for traditional Chinese medicine (TCM) therapy. Interventions and outcome: This patient was treated with the integrated treatment, mainly including empirical Chinese herbal formulas (500 mL/day for 3-months), multi-glycoside of Tripterygium wilfordii Hook.f. (GTW) (90 mg/day for 3-months) and Losartan (50 mg/day for 3-months). His heavy proteinuria and clinical conditions were significantly improved after continuous treatment for 3-months and basically stable for nearly 3-years during the follow-up. Conclusions: Based on a variety of conventional drugs in clinic, the combined treatment of empirical Chinese herbal formulas and GTW was significantly effective in reducing massive proteinuria in non-IgA MsPGN patients, which is different from hormonotherapy.
Export Options
About this article
Cite this article as:
Huang Yan-ru, Heaton Thomas, Wan Yi-gang, Mao Zhi-min and Yang Jing-jing, A Case of Heavy Proteinuric Non-IgA Mesangial Proliferative Glomerulonephritis Ameliorated by Chinese Herbal Medicines, Current Traditional Medicine 2015; 1 (3) . https://dx.doi.org/10.2174/221508380103151231142116
DOI https://dx.doi.org/10.2174/221508380103151231142116 |
Print ISSN 2215-0838 |
Publisher Name Bentham Science Publisher |
Online ISSN 2215-0846 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Update on the Role of Neutrophils in Atherosclerotic Plaque Vulnerability
Current Drug Targets Islet Amyloid Polypeptide (IAPP): A Second Amyloid in Alzheimer's Disease
Current Alzheimer Research Editorial (Thematic issue: Possible Therapeutic Targets for the Treatment of Diabetic Retinopathy: Evidences from Experimental Models)
Current Clinical Pharmacology Outcomes of Anticoagulant Therapy with Low-Molecular-Weight Heparin (LMWH) and Warfarin for Thromboangiitis Obliterans (TAO)
Current Vascular Pharmacology A Review of Current Treatment Strategies for Varicose Veins
Recent Patents on Cardiovascular Drug Discovery Closing in on Biliary Atresia
Current Pediatric Reviews Pharmacological Regulation of Dyslipoproteinaemia in Insulin Resistant States
Current Vascular Pharmacology Long-Term Effects of Perinatal Glucocorticoid Treatment on the Heart
Current Pediatric Reviews Bioactivity and Pharmacological Actions of Carbon Monoxide-Releasing Molecules
Current Pharmaceutical Design Targeting Leukocytes in Immune Glomerular Diseases
Current Medicinal Chemistry Experimental Benefits of Sex Hormones on Vascular Function and the Outcome of Hormone Therapy in Cardiovascular Disease
Current Cardiology Reviews Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: A Review of Recent Clinical Trials
Reviews on Recent Clinical Trials Clinical Pharmacology of Frequently Used Intravenous Drugs During Bariatric Surgery in Adolescents
Current Pharmaceutical Design α-Amylase Inhibition: Some Practical Considerations
Current Enzyme Inhibition III. Angiogenesis: Complexity of Tumor Vasculature and Microenvironment
Current Pharmaceutical Design Calcium and Vitamin D Supplementation. Myths and Realities with Regard to Cardiovascular Risk
Current Vascular Pharmacology The Effects of Lipid-Regulating Therapy on Haemostatic Parameters
Current Pharmaceutical Design Treatment of Experimental Myocarditis via Modulation of the Renin-Angiotensin System
Current Pharmaceutical Design Moving Troponin Testing into the 21st Century: Will Greater Sensitivity Be Met with Greater Sensibility?
Cardiovascular & Hematological Disorders-Drug Targets The Supremacy of Synergism: A Comparison of Anticancer Activity of Rhizome Extract of Bistorta Amplexicaulis and Gallic Acid in Cancer Cell Lines and Primary Cells
Current Nutraceuticals